Anabolic steroidAndrogenInjectableBoldenone ester

Boldenone Acetate

Also known as Bold Ace · EQ Acetate

Written by enwyReviewed 15 Jul 20261 sources0 comments

A very short-acting acetate ester of boldenone, requiring near-daily injection. Effects mirror boldenone (Equipoise): gradual quality lean gains, appetite and red-cell stimulation, moderate estrogenic activity. Ester-specific human data are essentially absent.

01 Overview

Boldenone acetate is boldenone esterified with acetic acid, giving the shortest release of any boldenone preparation. It is an uncommon, mostly underground-market product; the standard commercial form of boldenone is the long-acting undecylenate (Equipoise). The acetate's fast clearance demands daily or every-other-day injection to maintain stable levels.

Because the active hormone is boldenone, the qualitative effects and side effects match EQ, with only the release kinetics differing. There are no meaningful human trials of this ester, so it is characterised by inference from boldenone and graded low.

02 Mechanism

The acetate ester is rapidly hydrolysed to release boldenone, which acts on the androgen receptor, aromatises modestly, and strongly stimulates erythropoiesis and appetite.

03 Dosing

Tier	Dose	Route	Notes
Common (boldenone-equivalent)	300–500 mg/wk	IM	Very short ester; daily or EOD injections. Inferred from boldenone.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Increased lean massGradual quality gains typical of boldenone.	slow, steady	Observational
Increased appetiteCommonly reported appetite boost.		Anecdotal
Increased red blood cellsRaised haematocrit and endurance.		Observational

05 Side effects

Effect	Severity	Frequency	Evidence
HPTA suppressionSuppresses endogenous testosterone and spermatogenesis.	Severe	Universal	Clinical
ErythrocytosisMarked rise in haematocrit.	Moderate	Common with boldenone	Observational
Injection frequency burdenNear-daily injections raise the risk of site irritation and poor adherence.	Mild	Inherent to ester	Observational

06 Legal status

United States

Schedule III controlled substance

as of Jan 2026

United Kingdom

Class C controlled drug

as of Jan 2026

07 References

Boldenone pharmacology and anabolic profileVeterinary/sports pharmacology literature

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.